NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety

Table 8 Adverse event structure for asunaprevir

	Lok et al[35] AI447-011		Suzuki et al[36]
	ASV + DCV + conventional therapy(n = 10)	ASV + DCV(n = 11)	Null response (n = 21)	Contraindications to IFN-based therapy (n = 22)
Diarrhea	70.0%	72.7%	43%	9%
Fatigue	70.0%	54.5%	-1	-1
Headache	50.0%	45.5%	38%	27%
Nausea	50.0%	18.2%	-1	-1
Coughing	20.0%	27.3%	-1	-1
Subfebrile temperature	27.3%	10.0%	14%	23%

¹Adverse events are not shown because they were observed in fewer than 3 patients. AE: Adverse event; ASV: Asunaprevir; DCV: Daclatasvir; IFN: Interferon.